STAT+: FDA后Overton时代的7个关键问题
STAT+: 7 burning questions about the FDA’s post-Overton future
白宫周二晚间撤回对Heidi Overton担任FDA专员的提名,令卫生委员会参议员震惊。FDA自今年5月起便没有正式负责人,特朗普政府已更换三位领导人,Overton被撤后将可能迎来第四位。该机构面临多项挑战:资助药物审评的用户费用需重新授权,且需应对AI在科研中的应用及中美生物科技竞争。
WASHINGTON — The White House pulled its nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday evening, startling senators on the health committee and introducing new questions about the future of the FDA.
The decision is a blow to an agency that thrives on stability and has been without a permanent head since May, though it was beginning to enjoy a period of relative normalcy under acting commissioner Kyle Diamantas. The FDA is on its third leader of this Trump administration, and whoever replaces Overton as nominee could be the fourth.
The FDA is facing a number of challenges. The user fees that fund the agency’s drug reviews need to be reauthorized, a process that may be complicated by Democrats’ sweeping midterm election wins. And leaders are confronting the rise of artificial intelligence in scientific research and push to compete with China’s biotech industry.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com